LKB1 Tumor Suppressor: Therapeutic Opportunities Knock when LKB1 Is Inactivated

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Liver kinase B1 (LKB1) is recognized as a tumor suppressor gene due to its association with hereditary cancer syndromes and inactivation in various cancers like lung, melanoma, and cervical cancers.
• Unlike typical tumor suppressors, LKB1's function includes suppressing proliferation to enhance cell survival during energetic stress via AMPK signaling.
• This unique pro-survival role has identified specific vulnerabilities in LKB1-deficient cells.

Purpose of the Study:

• To review the known vulnerabilities of LKB1-mutant cancer cells.
• To discuss the therapeutic potential of targeting these vulnerabilities with existing or novel reagents.
• To highlight a novel treatment strategy for cancers with defective LKB1.

Main Methods:

• Literature review of studies on LKB1 function and cancer.
• Analysis of LKB1-regulated pathways, particularly AMPK signaling.
• Identification of therapeutic agents targeting LKB1-null cell defects.

Main Results:

• LKB1-mutant cells exhibit specific vulnerabilities related to energetic stress sensing.
• Reagents like phenformin exploit these defects, selectively targeting LKB1-null cells.
• Targeted agents induce cell death in the absence of functional LKB1.

Conclusions:

• Defective LKB1 in cancer cells presents unique therapeutic opportunities.
• Targeting LKB1-null cell vulnerabilities offers a novel strategy for cancer treatment.
• Further development of reagents exploiting these defects holds promise for LKB1-mutant cancers.